

# Joseph Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7720337/publications.pdf>

Version: 2024-02-01

115  
papers

6,481  
citations

101543

36  
h-index

66911

78  
g-index

117  
all docs

117  
docs citations

117  
times ranked

10032  
citing authors

#	ARTICLE	IF	CITATIONS
1	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 2017, 112, 18-35.	0.4	672
2	American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology, 2015, 148, 215-219.	1.3	634
3	Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 2015, 61, 191-199.	7.3	464
4	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology, 2020, 159, 320-334.e27.	1.3	330
5	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver International, 2016, 36, 807-816.	3.9	270
6	AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology, 2020, 159, 739-758.e4.	1.3	254
7	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 2021, 160, 912-918.	1.3	245
8	Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients. Annals of Internal Medicine, 2014, 160, 369-379.	3.9	214
9	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 2020, 158, 1822-1830.	1.3	202
10	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology, 2016, 151, 1131-1140.e5.	1.3	199
11	Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology, 2020, 72, 1169-1176.	7.3	194
12	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology, 2016, 150, 419-429.	1.3	166
13	Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology, 2019, 156, 431-445.	1.3	133
14	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology, 2017, 152, 1536-1543.	1.3	121
15	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology, 2021, 160, 1384-1393.	1.3	121
16	Liver transplantation for alcoholic liver disease: Current concepts and length of sobriety. Liver Transplantation, 2004, 10, S31-S38.	2.4	111
17	Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. International Journal of Drug Policy, 2015, 26, 922-935.	3.3	95
18	Prevalence of Chronic Hepatitis B Virus Infection in the United States. American Journal of Gastroenterology, 2020, 115, 1429-1438.	0.4	92

#	ARTICLE	IF	CITATIONS
19	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	1.3	90
20	Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase $\leq 40$ IU/L and significant hepatic fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 349-358.	3.7	86
21	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	3.7	86
22	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	3.7	85
23	Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 8294.	3.3	81
24	Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1857-1867.	4.5	79
25	American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2017, 152, 1578-1587.	1.3	69
26	New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. <i>Health Affairs</i> , 2016, 35, 1893-1901.	5.2	63
27	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the <sc>US</sc>— the <sc>ENUMERATE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 134-144.	3.7	63
28	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2416-2422.	4.4	60
29	Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2019, 69, 959-973.	7.3	60
30	Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. <i>PLoS ONE</i> , 2015, 10, e0135645.	2.5	59
31	Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-12.	1.4	49
32	Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2017, 112, 828-832.	0.4	47
33	AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. <i>Gastroenterology</i> , 2020, 159, 1935-1948.e5.	1.3	44
34	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	43
35	An expert consensus for the management of chronic hepatitis B in Asian Americans. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1181-1200.	3.7	40
36	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	3.7	37

#	ARTICLE	IF	CITATIONS
37	Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 230-238.	1.4	36
38	Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1061-1069.	3.7	35
39	Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, 24-32.	3.7	35
40	AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. <i>Gastroenterology</i> , 2021, 161, 1011-1029.e11.	1.3	29
41	Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis and Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1262-1266.	4.4	26
42	FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. <i>Hepatology</i> , 2017, 66, 1286-1295.	7.3	26
43	Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption - an observational cross-sectional study. <i>BMC Gastroenterology</i> , 2020, 20, 1.	2.0	26
44	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	5.9	26
45	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 184-191.	3.1	25
46	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , 2018, 13, e0196908.	2.5	23
47	Disparities in hepatitis C testing in U.S. veterans born 1945-1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265.	3.7	22
48	Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 17081.	3.3	22
49	Pathophysiology of Hepatic Encephalopathy. <i>Clinics in Liver Disease</i> , 2020, 24, 175-188.	2.1	22
50	Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1684-1693.	2.8	21
51	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1811-1819.e4.	4.4	20
52	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. <i>Cancer Causes and Control</i> , 2020, 31, 321-332.	1.8	20
53	Endoscopic Approach to the Treatment of Gastrointestinal Bleeding. <i>Techniques in Vascular and Interventional Radiology</i> , 2004, 7, 123-129.	1.0	19
54	Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 2025-2034.	2.6	19

#	ARTICLE	IF	CITATIONS
55	Optimal timing for hepatitis C therapy in <sc>US</sc> patients eligible for liver transplantation: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1090-1101.	3.7	18
56	Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000056.	2.7	18
57	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	3.3	18
58	Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. <i>Medical Care</i> , 2019, 57, 279-285.	2.4	18
59	Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis. <i>Liver International</i> , 2016, 36, 634-641.	3.9	16
60	Psychometric properties of the <sc>PROMIS</sc> short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1001-1011.	3.7	16
61	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	2.6	16
62	Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000066.	2.7	15
63	Determinants of Liver Complications Among HIV/Hepatitis B Virus Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	2.1	14
64	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	1.8	13
65	Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. <i>Digestive Diseases and Sciences</i> , 2018, 63, 61-71.	2.3	13
66	&lt;p&gt;Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data&lt;p&gt;. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 115-123.	2.5	13
67	Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999-2012. <i>Hepatology</i> , 2016, 64, 681-682.	7.3	12
68	Oral Cyanobacteria and Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 221-229.	2.5	12
69	The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. <i>Cancer Medicine</i> , 2019, 8, 5948-5958.	2.8	11
70	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	3.9	11
71	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv109.	0.9	10
72	Budd-Chiari Syndrome. <i>Clinics in Liver Disease</i> , 2020, 24, 453-481.	2.1	9

#	ARTICLE	IF	CITATIONS
73	Spotlight: COVID-19 PPE and Endoscopy. <i>Gastroenterology</i> , 2020, 159, 759.	1.3	9
74	Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. <i>Patient</i> , 2016, 9, 241-249.	2.7	8
75	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. <i>BMC Gastroenterology</i> , 2019, 19, 52.	2.0	8
76	Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-17.	1.4	8
77	Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. <i>ACG Case Reports Journal</i> , 2016, 3, 42-44.	0.4	8
78	NASH and the Gut Microbiome: Implications for New Therapies. <i>Clinical Liver Disease</i> , 2022, 19, 97-100.	2.1	8
79	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. <i>Journal of Hepatology</i> , 2021, 75, 1312-1322.	3.7	6
80	Prevention and Management of Hepatitis B in Healthcare Professionals. <i>Current Hepatology Reports</i> , 2019, 18, 1-8.	0.9	5
81	Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 953-960.	0.5	5
82	Management of Hepatitis C in Special Populations: HIV Coinfection, Renal Disease, and Decompensated Cirrhosis. <i>Clinical Liver Disease</i> , 2020, 16, 29-31.	2.1	5
83	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	3.9	4
84	Introduction of Clinical Practice Update Committee Articles. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 4.	4.4	4
85	Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. <i>Current Hepatology Reports</i> , 2019, 18, 249-258.	0.9	4
86	Retreatment of chronic hepatitis C virus infection. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4, 97-103.	0.6	4
87	Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. <i>Current Hepatitis Reports</i> , 2010, 9, 65-74.	0.3	3
88	Developing therapies to treat hepatitis C infection in post-liver transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 165-174.	1.8	3
89	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 125-134.	5.0	3
90	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-8.	1.4	3

#	ARTICLE	IF	CITATIONS
91	The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. <i>Current Hepatitis Reports</i> , 2011, 10, 134-141.	0.3	2
92	Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. <i>Journal of Substance Abuse Treatment</i> , 2016, 68, 62-67.	2.8	2
93	Management of Chronic Hepatitis C in End-stage Renal Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 287-294.	2.2	2
94	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. <i>Scientific Reports</i> , 2020, 10, 18729.	3.3	2
95	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	2.0	2
96	Care of the Patient With Abnormal Liver Test Results. <i>Annals of Internal Medicine</i> , 2021, 174, ITC129-ITC144.	3.9	2
97	Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 206-227.	1.4	2
98	Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 424-429.	1.6	2
99	Waking Up the Sleeping Giant: Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy. <i>Clinical Liver Disease</i> , 2020, 16, 198-203.	2.1	1
100	Lupus cerebritis and steroid psychosis in mixed connective tissue disorder. <i>Yale Journal of Biology and Medicine</i> , 2004, 77, 63-9.	0.2	1
101	Advancing the science and practice of gastroenterology and hepatology. <i>BMJ Open Gastroenterology</i> , 2014, 1, e900001.	2.7	0
102	Diagnosis, Management, and Prevention of Hepatitis B Reactivation. <i>Current Hepatology Reports</i> , 2015, 14, 184-194.	0.9	0
103	Current Management of Hepatitis B in 2016. <i>Current Hepatology Reports</i> , 2016, 15, 266-270.	0.9	0
104	Introduction to Clinical Practice Update Committee Articles. <i>Gastroenterology</i> , 2016, 151, 45.	1.3	0
105	Response to Liu et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 1749-1750.	0.4	0
106	Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations. <i>Current Hepatology Reports</i> , 2018, 17, 83-87.	0.9	0
107	Increasing contribution of non-alcoholic fatty liver disease to hepatocellular carcinoma incidence and mortality in U.S. Medicare. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 506-508.	1.5	0
108	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-CO13 HEPAVIH)". <i>Journal of Hepatology</i> , 2020, 72, 592-593.	3.7	0

#	ARTICLE	IF	CITATIONS
109	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 5395-5404.	2.8	0
110	Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 397-397.	1.6	0
111	Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 279-299.	2.2	0
112	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 530-534.	2.1	0
113	The ALT upper reference interval debate: Blame it on the alcohol. <i>Clinica Chimica Acta</i> , 2022, 526, 62-65.	1.1	0
114	Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. <i>Hepatology</i> , 2022, 75, 1664-1666.	7.3	0
115	Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2022, , .	3.7	0